Research Advance of Gene Mutation and Targeted Drug Therapy in Childhood Acute Myeloid Leukemia --Review.
10.19746/j.cnki.issn.1009-2137.2022.02.052
- Author:
Cheng-Kan DU
1
;
Ying LU
2
Author Information
1. Department of Pathophysiology, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
2. Department of Pathophysiology, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China,E-mail: stove@shsmu.edu.cn.
- Publication Type:Review
- Keywords:
acute myeloid leukemia;
children;
gene mutation;
targeted therapy
- MeSH:
Adult;
Child;
Cytarabine;
Humans;
Leukemia, Myeloid, Acute/genetics*;
Mutation;
Myeloproliferative Disorders;
Nuclear Proteins/genetics*;
Nucleophosmin;
Prognosis;
fms-Like Tyrosine Kinase 3/genetics*
- From:
Journal of Experimental Hematology
2022;30(2):631-635
- CountryChina
- Language:Chinese
-
Abstract:
The clinical therapeutic regimen for acute myeloid leukemia (AML) is not significantly different between adults and children, which is mostly based on IA (idarubicin and cytosine arabinoside) induction chemotherapy. With the rapid development of sequencing technique, people's understandings towards the molecular and biological abnormalities of AML are increasing, diverse AML gene mutation-based targeted drugs have been rapidly developed and applied. In this review, several commonly gene mutations in AML (such as FLT3, NPM1 and C/EBPA) was described, and the therapeutic effects and differences of targeted drugs that used in clinical treatment or had been reported (like tyrosine kinase inhibitor, IDH1 mutation inhibitor and epigenetic modification inhibitor) in child and adult AML patients were summrized.
